Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Capital Expenditures (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of Capital Expenditures readings, the most recent being $2000.0 for Q4 2025.

  • Quarterly Capital Expenditures fell 81.82% to $2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Dec 2025, down 50.0% year-over-year, with the annual reading at $9000.0 for FY2025, 50.0% down from the prior year.
  • Capital Expenditures hit $2000.0 in Q4 2025 for Oramed Pharmaceuticals, down from $4000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $372000.0 in Q3 2021 and bottomed at $2000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $69647.1, with a median of $20000.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 323.4% in 2023, while the deepest fall reached 99.03% in 2023.
  • Oramed Pharmaceuticals' Capital Expenditures stood at $372000.0 in 2021, then dropped by 17.2% to $308000.0 in 2022, then plummeted by 99.03% to $3000.0 in 2023, then soared by 266.67% to $11000.0 in 2024, then crashed by 81.82% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Capital Expenditures are $2000.0 (Q4 2025), $4000.0 (Q2 2025), and $3000.0 (Q1 2025).